Literature DB >> 14520162

Lamotrigine treatment for post-stroke pathological laughing and crying.

Rajamannar Ramasubbu1.   

Abstract

Pathologic laughing and crying (PLC) is a common distressing and socially disabling condition in stroke patients. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), have been increasingly recognized as the treatment of choice for pathologic crying (PC). However, little is known about etiologies and other treatment options for various clinical manifestations of PLC. This case report illustrates the beneficial effect of lamotrigine, a novel antiepileptic drug with antidepressant and mood-stabilizing properties in post-stroke PLC. A 60-year-old woman developed PLC after an ischemic stroke affecting the left frontal and temporal lobes. She was treated with lamotrigine initially at the dose of 50 mg a day, which was gradually increased to 100 mg a day over a 4-week period. There was a significant and rapid recovery in both laughing and crying components of PCL with lamotrigine treatment. The symptoms of pathologic laughing have shown a better response to lamotrigine than PC. Controlled investigations are needed to evaluate the beneficial as well as the differential effects of lamotrigine on PLC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14520162     DOI: 10.1097/00002826-200309000-00006

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  11 in total

Review 1.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 2.  Current concepts in the pharmacotherapy of pseudobulbar affect.

Authors:  Erik P Pioro
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

3.  [Amyotrophic lateral sclerosis: management of bulbar symptoms].

Authors:  P Kraft; M Beck; A Grimm; C Wessig; K Reiners; K V Toyka
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

4.  The causes and treatment of pseudobulbar affect in ischemic stroke.

Authors:  Preethi Balakrishnan; Howard Rosen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 5.  Dextromethorphan/quinidine sulfate for pseudobulbar affect.

Authors:  Howard Rosen
Journal:  Drugs Today (Barc)       Date:  2008-09       Impact factor: 2.245

6.  Two cases of emotional disorder after middle cerebral artery infarction showing distinct responses to antidepressant treatment.

Authors:  Kengo Shimoda; Mahito Kimura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-23       Impact factor: 2.570

Review 7.  Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Authors:  Kerri A Schoedel; Sarah A Morrow; Edward M Sellers
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-26       Impact factor: 2.570

Review 8.  Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.

Authors:  Erik P Pioro
Journal:  Neurol Ther       Date:  2014-06-17

Review 9.  Post-stroke Mood and Emotional Disturbances: Pharmacological Therapy Based on Mechanisms.

Authors:  Jong S Kim
Journal:  J Stroke       Date:  2016-09-30       Impact factor: 6.967

10.  Pathological Laughter in a Female with Multiple Episodes of Stroke and Subdural Hematoma.

Authors:  Sujita Kumar Kar; Sushanta Kumar Sahoo
Journal:  Indian J Psychol Med       Date:  2017 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.